Author

Nataliia Tsarynna

Observed institutions: Goethe University Frankfurt, Agaplesion Markus Hospital

OpenAlex ID: A5046680000

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

2023 · Brian G Feagan, Bruce E Sands, et al. · The Lancet. Gastroenterology & hepatology · 246

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

2024 · Marc Ferrante, Marc Ferrante, et al. · The Lancet · 120

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

2023 · Laurent Peyrin-Biroulet, Jessica R. Allegretti, et al. · Gastroenterology · 104

Histologic and combined histologic–endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results

2026 · Vipul Jairath, Fernando Magro, et al. · Journal of Crohn s and Colitis

Works count: 6

Citation count: 716

H-index: 5

I10-index: 5